SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
📊 The burden of hearing loss in Africa is rising, with projections estimating that 54 million people will be affected by 2030 if no action is taken. This alarming increase highlights the urgent need for policy advocacy and improved access to ear and hearing care services.
Discover the key findings from the WHO report and the steps needed to address this pressing issue.
#SyenzaNews #HearingHealth #PublicHealth
📊 Turkey’s pharmaceutical sector is on the rise! The latest “August 2024 Foreign Trade Analysis” offers a deep dive into the performance and dynamics of foreign trade, showcasing a 3.5% increase in total exports. 🌍 Discover the insights and market trends shaping the future of the pharmaceutical industry in Türkiye.
#SyenzaNews #PharmaceuticalIndustry #TradeAnalysis #Türkiye
🌍 Celebrating a decade of **ethical collaboration** among healthcare leaders! Health Policy Watch explores the groundbreaking achievements and future directions of this international consensus. By uniting efforts, we can tackle complex health challenges more effectively.
Read more about the role of ethical collaboration in shaping global health outcomes!
#SyenzaNews #GlobalHealth #EthicalCollaboration
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
